A5051457183- Prostate Cancer Treatment and Research
- Breast Cancer Treatment Studies
- Advanced Radiotherapy Techniques
- Hormonal and reproductive studies
- Prostate Cancer Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Estrogen and related hormone effects
- Radiopharmaceutical Chemistry and Applications
- Bone health and treatments
- Medical Imaging Techniques and Applications
- Breast Lesions and Carcinomas
- Breast Implant and Reconstruction
- Radiation Dose and Imaging
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Economic and Financial Impacts of Cancer
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- Cancer survivorship and care
- Colorectal Cancer Surgical Treatments
- Sexual Differentiation and Disorders
- Ureteral procedures and complications
- Advanced Breast Cancer Therapies
- Cancer, Stress, Anesthesia, and Immune Response
- Multiple Myeloma Research and Treatments
Beatson West of Scotland Cancer Centre
2014-2024
NHS Greater Glasgow and Clyde
2019-2023
Royal Alexandra Hospital
2013-2022
University of Glasgow
2020
Bell Resources (Australia)
2015
Robert Bosch (United States)
2015
Brewster Place
2015
New Victoria Hospital
2015
Medical Research Council
2011
Mid Yorkshire Hospitals NHS Trust
2011
BackgroundWe aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior terms local cancer control and as safe an international standard 15-fraction regimen after primary surgery for early breast cancer. Here, we present 5-year results the FAST-Forward trial.MethodsFAST-Forward multicentre, phase 3, randomised, non-inferiority trial done at 97 hospitals (47 centres 50 referring hospitals) UK. Patients aged least 18 years...
Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced patient age clinicopathological factors. We hypothesise that partial-breast restricted to the vicinity of original tumour women at lower than average local will improve balance beneficial versus adverse effects compared with whole-breast radiotherapy.
Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcomes after 5-fr regimens. Ten-year results are presented.
Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the complications LHRHa and thromboembolic oral oestrogen.In this multicentre, open-label, randomised, phase 2 trial, we enrolled men locally advanced or metastatic scheduled start indefinite hormone therapy. Randomisation was by minimisation, in a 2:1 ratio, four self-administered patches (100 μg per 24...
<h3>Importance</h3> Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models human cancer, but clinical evidence is lacking. <h3>Objective</h3> To evaluate the role celecoxib as an addition to conventional therapy for women ERBB2 (formerly HER2)–negative primary cancer. <h3>Design, Setting, and Participants</h3> The Randomized European Trial (REACT) was a phase 3, randomized, double-blind study conducted 160...
Objectives To compare quality‐of‐life (QoL) outcomes at 6 months between men with advanced prostate cancer receiving either transdermal oestradiol ( tE 2) or luteinising hormone‐releasing hormone agonists LHRH a) for androgen‐deprivation therapy ADT ). Patients and methods Men locally metastatic participating in an ongoing randomised, multicentre UK trial comparing 2 versus a were enrolled into QoL sub‐study. was delivered via three four transcutaneous patches containing 100 μg/24 h....
Luteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol well testosterone, causing bone mineral density (BMD) loss. Transdermal is a potential alternative to LHRHa. To compare BMD change men receiving either LHRHa or patches (OP). Men with locally advanced metastatic PCa participating the randomised UK Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) trial (allocation ratio of 1:2...
Androgen deprivation therapy (ADT), usually achieved with luteinising hormone releasing analogues (LHRHa), is central to prostate cancer management. LHRHa reduce both testosterone and oestrogen are associated significant long-term toxicity. Previous use of oral oestrogens as ADT was curtailed because cardiovascular Transdermal (tE2) patches a potential alternative ADT, supressing without the oestrogen-depletion toxicities (osteoporosis, hot flushes, metabolic abnormalities) avoiding...
To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone-naïve metastatic prostate cancer (mPC) first year use outside a clinical trial.Patients West Scotland Cancer Network with newly diagnosed mPC were identified from regional multidisciplinary team meetings their treatment details collected electronic patient records. The rate febrile neutropenia, hospitalisations, time to progression, overall survival compared between those patients who received...
Residency programs leading to board certification are important for safe and competent Radiation Oncology (RO) practice. In some developing nations, there is a gap in this field. This work addresses the experience that was accomplished establish such program Iraq despite all challenges faces country under war.Descriptive report of faced still reeling from war, steps taken overcome these outcomes after graduation two classes.After over 18 months prerequisite technical logistical preparations,...
201 Background: Androgen-deprivation therapy (ADT) with a luteinising hormone-releasing hormone analogue (LHRHa) is widely used in the management of prostate cancer. LHRHa suppresses testosterone to castrate levels but can lead long term toxicities including osteoporosis, adverse metabolic effects and cardiovascular (CV) complications. Transcutaneous oestrogen an attractive potential alternative ADT. This approach circumvents first-pass hepatic metabolism so should avoid CV previously...
Our aim was to clinically commission an online seed matching image-guided radiotherapy (IGRT) protocol using modern hardware/software for patients undergoing prostate radiotherapy. An essential constraint achieve this within a busy centre without reducing patient throughput, which had been reported with other techniques.45 3 fiducial markers inserted into the and were imaged daily kilovoltage orthogonal images correction applied before treatment. A total of 1612 image pairs acquired analysed...
5067 Background: Androgen deprivation therapy (ADT) for prostate cancer with luteinising hormone-releasing hormone agonists (LHRH) reduces bone mineral density (BMD), as testosterone suppression also causes estrogen deficiency in men. Transdermal is a compelling alternative to LHRH it achieves similar castrate levels of but mitigates the cardiovascular toxicity associated oral (Langley et al. Lancet Oncology 2013;14:306-16) and may avoid depletion related toxicities including osteoporosis....
Abstract Introduction Patients with Inflammatory Bowel Disease and those previous rectal surgery may have challenges when undergoing prostate radiotherapy due to increased toxicity after which preclude them from having for their cancer. We need solutions that can minimize while maintaining the efficacy of patients. report on our experience using SpaceOAR Hydrogel Spacer as a solution radiation dose rectum reduce toxicities. Aim To assess benefits spacers following in patients who are at risk...